Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

Researchers leading the SWOG S1712 clinical trial have found that adding ... deep enough to warrant discontinuing treatment. A new preclinical model using CRISPR, an advanced technology that ...

A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.

Kineta will be trading under the symbol “KANT” on OTC PinkKineta will continue to pursue strategic alternatives as previously announcedTuHURA ...

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the ...

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...

"We are thrilled with the positive outcomes from our preclinical studies," Biolexis ... the biotech plans to conduct IND-enabling studies and begin human clinical trials early next year, chief ...